In laboratory medicine, a great forward step has been taken toward the pathway to a better understanding of quality, errors and risks to patient safety. An innovative approach for identifying all possible analytical errors, and systematically evaluating errors in individual patient results, is described in the paper by Michael Vogeser and Christoph Seger "Irregular analytical errors in diagnostic testing -a novel concept", in the current issue of the journal [1].A valuable source of information and a topic for further discussion, the paper (a) focuses on the need for a patient-centered approach for evaluating analytical quality; (b) reinforces the utility of appropriate metrics for measuring and improving upon quality in the analytical phase of laboratory testing; (c) stresses the importance of adequately defining the uncertainty of laboratory results and related "allowable uncertainty"; (d) stresses that a closer clinical-laboratory interface relationship, particularly in the post-post-analytical phase, is needed for adequately identifying the nature of "irregular (individual) analytical errors" -and providing valuable explanations and defining any corrective actions required; (e) is conducive to including the monitoring of "irregular analytical errors" as an additional quality indicator of the IFCC model of the quality indicator (MQI) project [2][3][4].The authors state that an "irregular analytical error is given when a test result generated from a sample using a routine method deviates from the reference measurement procedure (RMP) results generated for this sample more than the measurement error estimate of the routine method" [1]. They also state that an irregular analytical error should be generated, particularly in immunoassays, by: a cross-reaction, sometimes with compounds not listed by the manufacturer; anti-reagent antibodies (e.g. heterophilic antibodies); interference in signalgeneration (e.g anti-ruthenium antibodies); high levels of compounds (e.g. biotin in streptavidin/biotin binding-based immunoassays); matrix protein interferences (e.g. due to immunocomplexes, rheumatoid factors) and several other matrix effects (e.g. differential impact of matrix factors on target analyte and internal standard in LC-MS assays).